Caroline Dutriaux

Bordeaux, 33000, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 126 publications

primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.

primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 16, 2026

Erratum: BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.

Erratum: BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 24, 2025

BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.

BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 27, 2025

Brief Communication: Severe Immuno-Induced Rhinosinusitis With Deafness After Ipilimumab and Nivolumab Combination for Melanoma, and Review of the Literature.

Brief Communication: Severe Immuno-Induced Rhinosinusitis With Deafness After Ipilimumab and Nivolumab Combination for Melanoma, and Review of the Literature.

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

Published: June 09, 2025

Main histopathological difficulties in diagnosing atypical melanocytic proliferations using MPATH-Dx V2: impact on patient management based on 6006 files referred for second opinions.

Main histopathological difficulties in diagnosing atypical melanocytic proliferations using MPATH-Dx V2: impact on patient management based on 6006 files referred for second opinions.

Journal: Pathology

Published: May 05, 2025

Management of cardiac metastases of melanoma in the era of immunotherapy: a case series.

Management of cardiac metastases of melanoma in the era of immunotherapy: a case series.

Journal: Melanoma research

Published: March 25, 2025

Management of metastatic uveal melanoma: French expert consensus guidelines.

Management of metastatic uveal melanoma: French expert consensus guidelines.

Journal: Bulletin du cancer

Published: February 04, 2025

Brain metastases from Merkel cell carcinoma: A nationwide retrospective study.

Brain metastases from Merkel cell carcinoma: A nationwide retrospective study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 12, 2025

Improving diagnostic accuracy in atypical melanocytic tumors using p16 immunohistochemistry and 9p21 fluorescence in situ hybridization: analysis of 206 second opinion cases.

Improving diagnostic accuracy in atypical melanocytic tumors using p16 immunohistochemistry and 9p21 fluorescence in situ hybridization: analysis of 206 second opinion cases.

Journal: Scientific reports

Published: January 06, 2025

Antibiotics use decreases survival in cutaneous squamous cell carcinoma patients receiving immune checkpoint inhibitors.

Antibiotics use decreases survival in cutaneous squamous cell carcinoma patients receiving immune checkpoint inhibitors.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 15, 2024

Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohort.

Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohort.

Journal: Melanoma research

Published: November 11, 2024

Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study.

Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study.

Journal: The Lancet. Oncology

Published: October 23, 2024

Showing 1-12 of 126

Last Updated: 09/26/2026